Tivozanib has been approved by the FDA for the treatment of relapsed or refractory advanced renal cell carcinoma

August 2021: Tivozanib (Fotivda, AVEO Pharmaceuticals, Inc.), a kinase inhibitor, has been approved by the FDA for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after two or more prior systemic therapy.

TIVO-3 (NCT02627963), a randomised (1:1), open-label, multicenter trial of tivozanib versus sorafenib in patients with relapsed or refractory advanced RCC who had received two or three prior systemic treatments, including at least one VEGFR kinase inhibitor other than sorafenib or tivozanib, was used to assess efficacy. Patients were given either tivozanib 1.34 mg orally once daily for 21 consecutive days every 28 days or sorafenib 400 mg orally twice a day until disease progression or intolerable toxicity, whichever came first.

Progression-free survival (PFS) was the primary efficacy outcome measure, which was reviewed by a blinded independent radiological review committee. Overall survival (OS) and objective response rate were two other effectiveness objectives (ORR).

The median PFS in the tivozanib arm (n=175) was 5.6 months (95 percent CI: 4.8, 7.3), compared to 3.9 months (95 percent CI: 3.7, 5.6) in the sorafenib arm (HR 0.73; 95 percent CI: 0.56, 0.95; p=0.016). The median OS for the tivozanib and sorafenib groups was 16.4 months (95 percent CI: 13.4, 21.9) and 19.2 months (95 percent CI: 14.9, 24.2), respectively (HR 0.97; 95 percent CI: 0.75, 1.24). The ORR for the tivozanib arm was 18 percent (95 percent CI: 12 percent, 24 percent) and for the sorafenib arm was 8 percent (95 percent CI: 4 percent, 13 percent).

Fatigue, hypertension, diarrhoea, decreased appetite, nausea, dysphonia, hypothyroidism, cough, and stomatitis were the most prevalent (20%) adverse effects. Decreased sodium, increased lipase, and decreased phosphate were the most prevalent grade 3 or 4 laboratory abnormalities (5%).

The recommended tivozanib dose is 1.34 mg once day (with or without meals) for 21 days, followed by a 28-day break until disease progression or intolerable toxicity.

Reference : https://www.fda.gov/

Check details here.

Take second opinion on kidney cancer treatment

Send Details

Susan Hau

Website |  + postsBio ⮌

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

• Susan Hau

  https://cancerfax.com/author/susan/

  Best Cancer Hospitals in China 2025
• Susan Hau

  https://cancerfax.com/author/susan/

  Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
• Susan Hau

  https://cancerfax.com/author/susan/

  Treosulfan with fludarabine is approved by the USFDA as a preparative regimen for alloHSCT in adult and pediatric patients with AML or MDS
• Susan Hau

  https://cancerfax.com/author/susan/

  Fam-trastuzumab deruxtecan-nxki is approved by the USFDA for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer